EP1140368A1 - Dosing and delivering system - Google Patents
Dosing and delivering systemInfo
- Publication number
- EP1140368A1 EP1140368A1 EP00903272A EP00903272A EP1140368A1 EP 1140368 A1 EP1140368 A1 EP 1140368A1 EP 00903272 A EP00903272 A EP 00903272A EP 00903272 A EP00903272 A EP 00903272A EP 1140368 A1 EP1140368 A1 EP 1140368A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- piston
- valve
- damper
- reservoir
- fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012530 fluid Substances 0.000 claims abstract description 91
- 238000006073 displacement reaction Methods 0.000 claims abstract description 19
- 238000007789 sealing Methods 0.000 claims abstract description 13
- 238000004891 communication Methods 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims description 6
- 230000005611 electricity Effects 0.000 claims description 2
- 239000007921 spray Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 21
- 210000003041 ligament Anatomy 0.000 description 20
- 239000003814 drug Substances 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- -1 tetrahydrazoline Chemical compound 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000739 antihistaminic agent Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- 229920001971 elastomer Polymers 0.000 description 6
- 239000000806 elastomer Substances 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229940125715 antihistaminic agent Drugs 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 4
- 239000000850 decongestant Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- SSNZFFBDIMUILS-UHFFFAOYSA-N dodec-2-enal Chemical compound CCCCCCCCCC=CC=O SSNZFFBDIMUILS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960004305 lodoxamide Drugs 0.000 description 2
- RVGLGHVJXCETIO-UHFFFAOYSA-N lodoxamide Chemical compound OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl RVGLGHVJXCETIO-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229960000833 xylometazoline Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- CBOBADCVMLMQRW-UHFFFAOYSA-N 2,6-dimethyloctanal Chemical compound CCC(C)CCCC(C)C=O CBOBADCVMLMQRW-UHFFFAOYSA-N 0.000 description 1
- DPPDPATYPQFYDL-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-4-methyl-2,3-dihydropyrido[3,2-f][1,4]oxazepine-5-thione Chemical compound O1C(CCN(C)C)CN(C)C(=S)C2=CC=CN=C21 DPPDPATYPQFYDL-UHFFFAOYSA-N 0.000 description 1
- OIALAIQRYISUEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]e Polymers CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO OIALAIQRYISUEV-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- JTOUASWUIMAMAD-UHFFFAOYSA-N 7-[2-hydroxy-3-[4-(3-phenylsulfanylpropyl)piperazin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC(O)CN(CC1)CCN1CCCSC1=CC=CC=C1 JTOUASWUIMAMAD-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- OGEAASSLWZDQBM-UHFFFAOYSA-N Temelastine Chemical compound C1=NC(C)=CC=C1CC(C(N1)=O)=CN=C1NCCCCC1=NC=C(Br)C=C1C OGEAASSLWZDQBM-UHFFFAOYSA-N 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- YNKMHABLMGIIFX-UHFFFAOYSA-N benzaldehyde;methane Chemical compound C.O=CC1=CC=CC=C1 YNKMHABLMGIIFX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- YACLQRRMGMJLJV-UHFFFAOYSA-N chloroprene Chemical compound ClC(=C)C=C YACLQRRMGMJLJV-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000007590 electrostatic spraying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000002171 ethylene diamines Chemical class 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- MCPSMQGVSYDFLC-UHFFFAOYSA-N formaldehyde;2-octylphenol Chemical group O=C.CCCCCCCCC1=CC=CC=C1O MCPSMQGVSYDFLC-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- HTMIBDQKFHUPSX-UHFFFAOYSA-N methdilazine Chemical compound C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 HTMIBDQKFHUPSX-UHFFFAOYSA-N 0.000 description 1
- 229960004056 methdilazine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000631 nonopiate Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 229950003786 rocastine Drugs 0.000 description 1
- 229920002631 room-temperature vulcanizate silicone Polymers 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- VBSPHZOBAOWFCL-UHFFFAOYSA-N setastine Chemical compound C=1C=CC=CC=1C(C=1C=CC(Cl)=CC=1)(C)OCCN1CCCCCC1 VBSPHZOBAOWFCL-UHFFFAOYSA-N 0.000 description 1
- 229950003911 setastine Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229950004607 tazifylline Drugs 0.000 description 1
- 229950005829 temelastine Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B5/00—Electrostatic spraying apparatus; Spraying apparatus with means for charging the spray electrically; Apparatus for spraying liquids or other fluent materials by other electric means
- B05B5/025—Discharge apparatus, e.g. electrostatic spray guns
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/02—Membranes or pistons acting on the contents inside the container, e.g. follower pistons
- B05B11/028—Pistons separating the content remaining in the container from the atmospheric air to compensate underpressure inside the container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1001—Piston pumps
- B05B11/1015—Piston pumps actuated without substantial movement of the nozzle in the direction of the pressure stroke
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1042—Components or details
- B05B11/1052—Actuation means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1094—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle having inlet or outlet valves not being actuated by pressure or having no inlet or outlet valve
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B5/00—Electrostatic spraying apparatus; Spraying apparatus with means for charging the spray electrically; Apparatus for spraying liquids or other fluent materials by other electric means
- B05B5/16—Arrangements for supplying liquids or other fluent material
- B05B5/1691—Apparatus to be carried on or by a person or with a container fixed to the discharge device
Definitions
- the invention relates to a mechanical assembly for dosing and delivering a fluid.
- Devices for dosing and delivering a fluid are widely used in consumer goods or in pharmaceutical industry. Such devices for dosing and delivering a fluid should allow a good control of the quantity of fluid dosed, as well as a good control of the delivery of this fluid dose. In particular in the pharmaceutical industry, accurate control of both the quantity and the delivery are critical. Furthermore, it is desired to produce such devices in a reproducible and economical manner. It is the object of this invention to provide accurate dosing and delivery of a fluid by means of an economical dosing and delivery device.
- this object is accomplished in a dispensing device for a fluid, the dispensing device comprising a reservoir, a shaft, a back seal, a damper, a piston and a one-way valve, the back seal sealing a first end of the reservoir and being displaceable along the shaft, the valve being on the second end of the reservoir, the piston being fixed to one end of the shaft, the piston being located between the valve and the damper, the damper being also fixed to the shaft, the damper being located between the piston and the back seal, whereby the piston has an opened position and a closed position, the open position allowing fluid communication between the valve and the part of the reservoir between the piston and the back seal, the displacement of the piston between the opened and the closed position being induced by a displacement of the shaft along its own axis, the pressure in the area comprised between the valve and the piston reducing when the piston is moved from its closed position towards its opened position, the damper collapsing when the piston is moved from its closed position towards its opened position, the
- a device formed in accordance to the invention has a number of advantages. Since the devices comprises a piston having an opened position and a closed position allowing fluid communication between the valve and the reservoir, the quantity of fluid to dispense can be accurately controlled by displacing the desired quantity of fluid from the reservoir to the valve part by displacement of the piston from the closed to the opened position, the absence of a direct link between the reservoir and the valve avoiding uncontrolled emptying of the reservoir through the valve.
- the displacement of the piston towards the opened position will necessitate the application of a force threshold sufficient to overcome or at least to balance the pressure reduction and internal system friction forces, so that undesired displacement of the piston is avoided.
- the delivery of the dose is also accurately controlled via the combination of the use of the one way valve, of the piston, of the damper and of the back seal.
- the one way valve will allow delivery of the fluid only when the piston is displaced forward towards the valve, the speed of displacement of the piston being regulated by the size of the connecting passage provided in the damper combined with the fluid viscosity and applied mechanism force (e.g. spring force), thus allowing control on the speed of the fluid delivery through the valve.
- Figure 1 is a plan cross section view illustrating a dispensing device in accordance with the invention, the piston being in opened position.
- Figure 2 is a plan cross section view illustrating a dispensing device in accordance with the invention, the piston being in closed position.
- the invention relates to a dispensing device 1 or 2 for a fluid 10.
- fluid it should be understood that it includes liquids having various viscosities.
- Preferred fluids in a preferred embodiment of the invention are pharmaceutical fluids, but other applications are envisaged, such as air-freshening devices for example.
- the dispensing device 1 or 2 comprising a reservoir 11.
- the reservoir is typically a chamber in which the fluid 10 is to be found.
- the reservoir is substantially gas tight, thus avoiding or limiting chemical evolution due to contact with O 2 or H 2 0 vapour for example, or to retain air out of the device, in order to avoid discrepancies in the quantity of fluid to dose.
- the dispensing device further comprises a shaft 12, the shaft typically being an elongated element having as a main axis the more elongated direction, the shaft also normally comprising a part having a constant cross section in a plane normal to the main axis for allowing translation of a back seal 13, or being for example threaded to allow helical displacement of the a back seal 13 along the shaft 12.
- the device further comprises a back seal 13, the back seal 13 allowing sealing of the reservoir 11 , substantially independently from the quantity of fluid 10 contained in the reservoir 11.
- a back seal 13 the back seal 13 allowing sealing of the reservoir 11 , substantially independently from the quantity of fluid 10 contained in the reservoir 11.
- This can be obtained for example by having a main part of the reservoir 11 having a constant cross section in a plane perpendicular to the main axis of the shaft 12, the back seal 13 having a substantially identical cross section, the back seal 13 cross section being preferably marginally larger than the constant cross section of the reservoir 11 in order to achieve sealing, so that displacement of the back seal 13 along the shaft 12 allows to seal the reservoir 11 along the constant cross section at any level in the main part of the reservoir 11 having the constant cross section, thus allowing to seal in a gas tight manner a varying volume.
- the back seal 13 is made of a flexible and resilient material having an umbrella like shape, or even more preferably a double umbrella like shape, such that the seal is constantly pressing against the reservoir 11 on the cross section perimeter.
- the device 1 or 2 further comprises a damper 14.
- the damper is preferably a part made of a flexible material and having a umbrella like shape favouring collapsing during displacement in one direction and damping during displacement in the other direction.
- a piston 151 or 152 is also included in the device of the invention.
- the piston 151 or 152 is typically a part having a constant cross section being in a plane perpendicular to its main axis, this piston 151 or 152 being elongated along the main axis, the piston 151 or 152 being displaced in a part of the reservoir 11 which has a cross section in a plane normal to the main axis of the piston 151 or 152 which is substantially equal but preferably marginally smaller to the one of the piston 151 or 152 in order to allow good sealing.
- the main axis of the piston 151 or 152 is parallel of even aligned with the main axis of the shaft 12.
- the device further comprises a one-way valve 16.
- valve 16 By a one way valve it should be understood that in normal use, the valve 16 will allow passage of the fluid in one direction only.
- the valve 16 is a "self-seal" valve as described for example in principle in EP-A-0 597 601 , EP-A-0 395 380 or EP- A-0 160 336.
- a necessary feature of the device of the invention is that the back seal 13 is sealing a first end of the reservoir 11. This allows to use a gas tight reservoir 11 , which is useful to allow stability of the fluid product 10 and is necessary to the functioning of the device as will be described below.
- the back seal 13 should also be displaceable along the shaft 12, such displacement including linear or helical displacement for example.
- the valve 16 is on the second end of the reservoir 11. Indeed, the reservoir is normally elongated along the main direction of the shaft, and comprises two end only, the first one being sealed by the back seal 13 and the other comprising the valve 16.
- the piston 151 or 152 is fixed to one end of the shaft 12. Indeed, the piston 151 or 152 is used in the device 1 or 2 according to the invention to push a dose 100 of product towards the valve 16. In order to achieve this, the piston 151 or 152 being located between the valve 16 and the damper 14. The damper 14 is also fixed to the shaft 12, the damper 14 being located between the piston 151 or 152 and the back seal 13.
- the damper 14 is located in the part 110 of the reservoir 11 which is not containing a dose 100 ready to be dispensed.
- the device 1 or 2 according to the invention is mainly intended for multiple use, so that the damper 14 stands in the part of the reservoir 11 which contains a plurality of doses which are not ready to be dispensed as they are not located between the piston and the valve. It should be noted that the device 1 or 2 could also be suitable for single use.
- the piston 151 or 152 has an opened position 151 and a closed position
- the displacement of the piston between the opened 151 and the closed 152 position is induced by a displacement of the shaft 12 along its own axis, which is the main axis.
- the pressure in the area 100 comprised between the valve 16 and the piston reduces when the piston is moved from its closed position 152 towards its opened position 151 , thus generating a part vacuum. This allows to "suck in” a dose 100 of product from the part of the reservoir 11 located between the piston an the back seal into the part 100 between the valve and the piston when the piston goes in opened position 151.
- the damper 14 collapses when the piston is moved from its closed position 152 towards its opened position 151. This allows easing of the preparation for dispensing and avoids excessive opposite forces when the operator actuates the device, whereby movement or displacement of the piston from its closed position towards its opened position will prepare for opening the fluid communication 153 between the part of the reservoir between the piston and the back seal and the part 100 between the valve and the piston, in order to fill this last part with fluid by means of the pressure reduction or part vacuum mentioned above, the dose of fluid 100 being "sucked in” this part by the pressure reduction through the fluid communication 153 being ready to be dispensed when pushed by the piston through the valve.
- the piston has to move from its opened 151 towards its closed 152 position, thus moving the damper 14 as both the damper 14 and the piston are fixed to the shaft 12, the damper 14 moving through the fluid 10, thus creating a non-equilibrium in the sealed reservoir 1 1 between the part of the reservoir located between the damper 14 and the back seal 13 and the part of the reservoir 1 1 located between the damper 14 and the piston, this non-equilibrium being compensated by a flow in the connecting passage 140 situated in the damper 14, thus controlling the speed of ejection or delivery of the dose 100 ready to be dispensed through the valve 16 by control of the move of the piston.
- the piston will have a maximum speed depending marginally on the compressibility and mainly on the viscosity of the fluid and on the geometrical and/or mechanical characteristics of the device. Indeed, for example, the larger the connecting passage 140 or the higher the applied forward force to the shaft 12 the higher the maximum speed.
- the shaft is made out of a material conducting electricity, such as metal for example.
- the fluid is electrically charged prior to being dispensed.
- the device according to the invention is particularly suited for this application as charging of the fluid will be facilitated by the control on the flow. In particular, there is a maximum speed beyond which charging the fluid becomes difficult or impossible, so that a damped delivery allows good charging.
- the charge rate is matched to the fluid flow rate to achieve efficient electro-hydrodynamic atomisation of the fluid.
- the volume comprised between the piston in the opened position and the valve is of less than 100 ⁇ L
- control on delivery is such that the volume of fluid dispensed at each dispensing operation varies of less than 10% between each dispensing operation.
- the variation is of less than 5%.
- a compressed spring is located on the end of the shaft opposite to the one to which the piston is fixed, applying a force onto the shaft in a direction substantially parallel to the shaft axis.
- the connecting passage is a single opening provided in the damper, even more preferably a circular opening.
- a most preferred embodiment of the invention is obtained by integrating the device of the invention to the spray device as disclosed in the pending applications GB9806937.0 and GB9806939.6.
- a spray device is particularly suited for treatment of maladies affecting the nasal region, such as hay fever or congestion due to colds.
- the mucous membranes of the nasal cavity can be used as a convenient delivery site for drugs targeted at other areas of the body. See for example WO 92/11049 which discloses a pen shaped device for nasal administration of, particularly, insulin.
- a spray form is often convenient for such treatments. Treatment of the eyes can also conveniently be effected by a spray device.
- Preferred volume doses for such applications are generally low, down to less than 10 ⁇ l.
- an elastomeric valve particularly a slit valve
- the spray device is adapted to provide one or more unit doses of a fluid, each dose having a volume in the range from about 1 to about 100 ⁇ l, the device comprising an elastomeric, self-sealing valve having a fluid side and a delivery side, the valve opening to allow passage of the fluid when pressure is applied to fluid on the fluid side and sealing when the pressure is removed.
- the spray device is an electrostatic spray device which charges the spray before entry into the nostrils. Fluids
- the device of the invention preferably comprises a fluid reservoir containing a pharmaceutically acceptable fluid, the fluid comprising a pharmaceutically acceptable treatment agent selected from medicaments, flavours, salts, surfactants and mixtures thereof.
- the fluid optionally comprises other adjuvants dissolved or dispersed within it.
- the fluid can be aqueous or non-aqueous. Suitable aqueous fluids include water and mixtures of water with water-miscible solvents such as glycerol, propylene glycol, or alcohols such as ethanol or isopropyl alcohol.
- Aqueous emulsions can also be used, either water-in-oil or oil-in water emulsions.
- the fluid is an aqueous solution, dispersion or oil-in-water emulsion.
- Suitable non- aqueous fluids comprise polyethylene glycols, glycerol, propylene glycol, dimethyl isosorbide, silicone oils, ketones, ethers and mixtures thereof.
- the invention has particular application to low resistivity fluids, especially those having a bulk resistivity of less than 1 x 10 8 ohm. cm, preferably those having a resistivity of less than 1 x 10 4 ohm.cm, more preferably less than 1 x 10 3 ohm. cm.
- the fluid may comprise a resistivity modifier, such as a pharmaceutically acceptable salt, in order to bring the bulk resistivity within the required range.
- the fluid is preferably a pharmaceutically acceptable intranasal carrier.
- the nasal composition is isotonic, i.e., it has the same osmotic pressure as blood and lacrimal fluid.
- the desired isotonicity of the compositions of this invention may be accomplished using, for example, the sodium chloride already present, or other pharmaceutically-acceptable agents such as dextrose, boric acid, citric acid, sodium tartrate, sodium citrate, sodium phosphate, potassium phosphate, propylene glycol or other inorganic or organic solutes.
- Sodium chloride is preferred particularly for buffers containing sodium ions. Further examples of sodium chloride equivalents are disclosed in Remington's Pharmaceutical Sciences pp. 1491 -1497 (Alfonso Gennaro 18th ed. 1990), which is herein incorporated by reference.
- the fluid can comprise a wide range of medicaments.
- medicament is meant a drug or other substance intended to have a therapeutic effect on the body. Suitable levels of the medicament are from 0.001 to 20%, preferably from 0.01 to 5%, more preferably from 0.1 to 5%. It will be appreciated that the levels of specific medicaments will depend on many factors including their potency, safety profile, solubility / ease of dispersion and intended effect.
- the medicament when used, can be one which is intended to have an effect at the site of application, such as a decongestant, antihistamine or anti- inflammatory drug, or it may be intended for systemic absorption such as an anti-viral, anti-depressant, anti-emetic, anti-pyretic medicament or a hormone or such-like.
- the medicament can be soluble in the fluid or can be an insoluble, finely divided particulate liquid or solid dispersed within the fluid.
- Suitable decongestants include oxymetazoline, tramazoline, xylo- metazoline, naphazoline, tetrahydrazoline, pseudoephedrine, ephedrine, phenylephrine, their pharmaceutically acceptable salts, such as the hydrochlorides, and mixtures thereof.
- Preferred decongestants are selected from oxymetazoline, xylo- metazoline, their pharmaceutically acceptable salts and mixtures thereof.
- oxymetazoline hydrochloride which is soluble in water.
- the decongestant is preferably present at a concentration of from about 0.01 % to about 3.0%, more preferably from about 0.01 % to about 1%.
- Antihistamines useful to the present invention include, but are not limited to, fast-acting, histamine H-1 receptor antagonists. Such as
- H-1 receptor antihistamines may be selected from among the following groups of antihistamines: alkylamines, ethanolamines, ethylenediamines, piperazines, phenothiazines, piperidines.
- useful fast acting antihistamines include acrivastine, carbinoxamine, diphenhydramine, chloropheniramine, brom- pheniramine, dexchloropheniramine, doxylamine, clemastine, promethazine, trimeprazine, methdilazine, hydroxyzine, pyrilamine, tripelennamine, meclizine, triprolidine, azatadine, cyproheptadine, rocastine, phenindamine or pharmaceutically acceptable salts and mixtures thereof.
- antihistamines include terfenadine, azelastine, cetirizine, astemizole . ebastine, ketotifen, lodoxamide, loratadine, levocabastine, mequitazine, oxatomide, setastine, tazifylline.
- the antihistamine component is preferably present at a concentration of from about 0.01 % to about 3.0%, more preferably from about 0.01 % to about 1 %.
- the medicament can also be an anti-inflammatory agent such as a corticosteroid.
- an anti-inflammatory agent such as a corticosteroid.
- Particularly preferred agents within this class are glucocorticoids selected from the group consisting of beclo- methasone, flunisolide, fluticasone, memetasone, budesonide, pharmaceutically acceptable salts thereof and mixtures thereof.
- the anti- inflammatory agent is preferably present at a concentration of from about 0.001% to about 0.1%, more preferably from about
- xanthine derivatives such as caffeine and methylxanthine and the like; antiallergics; mucolytics; anti- cholinergics; non-opiate analgesics such as acetaminophen, acetylsalicylic acid, ibuprofen, etodolac, fenbuprofen, fenoprofen, ketorolac, flurbiprofen, indomethacin, ketoprofen, naproxen, pharmaceutically acceptable salts thereof and mixtures thereof; opiate analgesics such as butorphanol; leukotriene receptor antagonists; mast cell stabilisers such as cromolyn sodium, nedocromil and lodoxamide; lipoxygenase inhibiting compounds; and nicotin, insulin and calcinotin.
- non-opiate analgesics such as acetaminophen, acetylsalicylic acid, ibuprofen,
- flavouring and/or aromatic components can be used in the fluids of the invention.
- these include, for example, menthol, camphor, eucalyptol, benzaldehyde (cherry, almond); citral (lemon, lime); neral; decanal (orange, lemon); aldehyde C-8, aldehyde C-9 and aldehyde C-12 (citrus fruits); tolyl aldehyde (cherry, almond); 2,6- dimethyl-octanal (green fruit); 2-dodecenal (citrus, mandarin); and herbal components such as thyme, rosemary and sage oils.
- Additional aromatic components suitable for use in the present invention include those described in U.S. Patent 4.136.163 to
- the fluid can also comprise one or more pharmaceutically acceptable surfactants.
- surfactants can be useful for dispersing or emulsifying medicaments or flavours, for enhancing absorption across the nasal membrane or as treatment agents in their own right, such as for softening earwax.
- the surfactants can be anionic, nonionic, cationic or amphoteric, preferably they are nonionic.
- Typical nonionic surfactants useful herein include: polyoxyethylene derivatives of fatty acid partial esters of sorbitol anhydrides such as polysorbate 80; polyoxyethylene derivatives of fatty acids such as polyoxyethylene 50 stearate, as well as oxyethylated tertiary octyl phenol formaldehyde polymer (available from Sterling Organics as Tyloxapol) or mixtures thereof.
- the usual concentration is from 0.1% to 3% by weight.
- the fluid can also comprise one or more pharmaceutically acceptable salts.
- the salt can mineral salts such as e.g. sodium chloride, or salts of organic acids such as sodium citrate.
- the fluid can further comprise other ingredients such as thickeners, humectants, suspending aids, encapsulating aids, chelating agents and preservatives.
- the viscosity of the compositions may be maintained at a selected level using a pharmaceutically-acceptable thickening agent.
- suitable thickening agents include, for example, xanthan gum, methyl cellulose, microcrystalline cellulose, carboxymethyl cellulose, chitosan, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, carboxyvinyl polymer, carbomer, and the like or pharmaceutically acceptable salts thereof. Mixtures of such thickening agents may also be used.
- the preferred concentration of the thickener will depend upon the agent selected. The important point is to use an amount which will achieve the selected viscosity. Viscous compositions are normally prepared from solutions by the addition of such thickening agents.
- Fluids useful in the present invention can also comprise from about 0.01% to about 5% of a humectant to inhibit drying of the mucous membrane and to prevent irritation.
- a humectant to inhibit drying of the mucous membrane and to prevent irritation.
- Any of a variety of pharmaceutically-acceptable humectants can be employed including, for example sorbitol, propylene glycol, polyethylene glycol, glycerol or mixtures thereof.
- the concentration will vary with the selected agent, although the presence or absence of these agents, or their concentration is not an essential feature of the invention.
- a pharmaceutically-acceptable preservative is generally employed to increase the shelf life of the compositions of the present invention.
- preservatives including, for example, benzyl alcohol, parabens, phenylethyl alcohol, thimerosal, chlorobutanol, chlorhexidine gluconate, or lo
- benzalkonium chloride can be employed.
- the most preferred preservative system for use herein comprises a combination of benzalkonium chloride, chlorhexidine gluconate and disodium EDTA as a chelating agent.
- a suitable concentration of the preservative will be from 0.001 % to 2% based on the total weight, although there may be appreciable variation depending upon the agent selected.
- the device is adapted to provide one or more unit fluid doses, preferably multiple fluid doses, each preferably with a volume in the range of from about 1 to about 100 ⁇ l, more preferably from about 1 to about 20, more preferably from about 5 to about 15 ⁇ l.
- the dose volume is preferably pre-set but may be adjusted by the user to a desired volume.
- the device is a refill unit which may be part of a larger device and which may be changed or replaced.
- the device is preferably adapted to produce a spray having a fluid ligament, the ligament extending from the nosepiece and having a nosepiece end and a delivery end, the spray further comprising a spray cone diverging from the delivery end of the ligament.
- nosepiece end is meant the point at which a plane (hereinafter the nosepiece plane) drawn perpendicular to the axis of the ligament and just touching the exterior of the nosepiece would intersect the centre of the ligament.
- the ligament preferably has a length of from about 1 to about 20 mm, more preferably from about 1 to about 10 mm, yet more preferably from about 2 to about 8 mm, and especially from about 3 to about 6mm from the nosepiece end to the delivery end.
- the spray cone has a cone angle of from about 10 to about 90°, preferably 20 to about 50°, more preferably from about 30 to about 40°.
- the length of the ligament and the spray cone angle can be adjusted by varying the viscosity or surface tension of the fluid, by varying the fluid flow rate or exit velocity, or by changing the valve slit characteristics or valve material properties, or by varying the electrical field strength through applied voltage, potential gradient or by use of a field intensifying electrode.
- the total length of the ligament can be, and preferably is, longer than the length from the nosepiece end to the delivery end since the ligament preferably originates from a point on the device side of the nosepiece plane, such as from an elastomeric, self-sealing valve as disclosed herein, and passes through a passage in the nosepiece.
- the distance from the point of origin of the ligament to the nosepiece plane is in the range from about 2 mm to about 15 mm, preferably from about 3 to about 10 mm and more preferably from about 5 to about 9 mm.
- the nosepiece can be employed as a field intensifier which helps to control the ligament length.
- the nosepiece is preferably a non-conducting material such as a plastic which can be e.g. polypropylene but is preferably a soft thermoplastic elastomer which provides for greater comfort if held against the nose. Elastomers described herein for the self-sealing valve are also suitable for the nosepiece.
- Electrostatic devices suitable for ligament mode spraying are described in WO 96/40441 , in EP-A-501 ,725 and in co-pending application PCT/GB97/02746.
- the present device is a device according to embodiments of EP-A-501 ,725 or PCT/GB97/02746 in which a jet is created by mechanical means and an applied high voltage leads to the jet or ligament breaking up into a spray cone.
- Suitable jet velocities are from about 0.5 to about 8, preferably from about 1 to about 3 msN
- a suitable high voltage is in the range from about 1 kV up to about 15 kV, preferably from about 2kV to about 10kV and more preferably from about 2kV to about 5kV.
- the voltage can conveniently be applied, even within the constraints of a small hand-held device, from a low voltage (1.5V is sufficient) battery coupled to a step-up transformer.
- the battery is preferably of the long-life type and can be rechargeable.
- the generator can be activated by the user by means of an external switch which can also be used to mechanically prime the pump.
- the switch includes a metal portion by means of which the user completes an earth return path to the high voltage circuit.
- a suitable arrangement for the overall device construction is described in PCT/GB97/02746. In this way the user does not acquire a net charge. Alternate arrangements, whereby an alternating voltage is applied, can also be used to prevent charge build-up.
- the device is preferably activated to deliver the spray.
- the ligament of the spray extends through the nostril opening, into the vestibule and preferably to within a short distance of the nasal valve opening, before breaking up to form the spray cone.
- the device preferably comprises an elastomeric, self-sealing exit valve having a fluid side and a delivery side, the valve opening to allow passage of the fluid when pressure is applied to fluid on the fluid side and sealing when the pressure is removed.
- clean stop is achieved by having the piston ending its forward movement in a pressure relief chamber (wider diameter area) resulting in a immediate pressure drop and resulting valve closure.
- exit valve is meant that the elastomeric valve is the final dispensing valve and that there are no other elements of the device which mechanically, restrict or modify the flow of the fluid on the downstream side of the valve.
- the valve is a slit valve.
- the valve can comprise a single slit or tow or more intersecting slits, to form a cross shape for example.
- the valve comprises a single slit.
- the valve can be flat it is preferably dome-shaped by which is meant a non-planar valve having a recess such as with a hemispherical or frustoconical dome.
- the valve is essentially in the form of a hemispherical dome having a flange along its perimeter so that a collar can be fitted to retain the valve in the device.
- the diameter of the valve, including the flange, is typically from about 2 to about 6 mm with the dome portion having a diameter of from about 1 to about 4 mm, typically about 2.5mm and a thickness from inside to out of from about 0.5 to about 1.5 mm, suitably about 1 mm.
- the valve need not be of uniform thickness.
- the valve dome's exterior surface is hemispherical whereas the internal surface is formed with a small flat at the top of the dome where the slit is formed.
- Suitable slit widths are from about 50 to about 400 ⁇ m, preferably from about 150 to about 250 ⁇ m. It is to be understood that the slit width refers to the longest dimension of the slit when first created.
- elastomer herein refers to a material which is both elastically compressible and elastically extensible.
- elastomers can be used, including but not limited to polyurethanes; chloroprene, butyl, butadiene and styrene- butadiene rubbers, and silicone elastomers such as 2 part room temperature vulcanising (RTV) silicones.
- RTV room temperature vulcanising
- Suitable silicone RTVs are available under the trademark NuSil and have a hardness of from about 30 to about 80 Shore A, preferably from about 40 to about 70 Shore A.
- the elastomers can optionally be mixed with a suitable plasticiser or foaming agent to make them more compressible.
- the elastomer may also have other materials dispersed within it in order to modify its properties, such as its conductivity. If elastomers of low tear strength are employed, the slit width may grow if the slit is held open for a prolonged period of time.
- the slit valve can be formed by piercing an injection or compression moulded elastomeric seal, of the same dimensions and shape as the intended valve, with a pin having a sharpened tip.
- the slit width is roughly proportional to the pin width.
- the pin can be a flat blade or can have a polygonal or round cross- section.
- the pin preferably has a polygonal or, especially, a round cross-section.
- Suitable pin diameters are from about 100 to 350, more preferably from 150 to 250 ⁇ m in diameter.
- silicone elastomers it is preferred that the piercing pin is withdrawn rapidly after forming the slit to avoid undesired slit growth.
- the geometry of the elastomeric seal and the method of piercing have a significant effect on the effectiveness and reproducibility of slit formation. More reliable slit formation is obtained if the seal is pierced from the inside of the dome rather than from the outside.
- the valve normally opens when pressure is applied to fluid on the fluid side and seals when the pressure is removed.
- the applied pressure is suitably in the range from about 200 to about 5000 mbar (20 to 500 kPa), preferably from about 500 to about
- the flow rate through the valve is generally proportional to the pressure applied and is suitably in the range from about 5 to about 50, more preferably from about 5 to about 30 ⁇ ls "1 .
- a straight fluid ligament with an exit velocity of from about 0.5 to about 8 preferably from about 1 to about 3 ms "1 is obtained.
- the diameter of the issuing ligament is partly determined by the flow rate and is generally less than the width of the slit valve. Depending on the flow rate, ligament diameters of less than 50 ⁇ m can be achieved, even when a valve slit width of 200 ⁇ m is employed.
- the ligament diameter strongly influences the particle size of the spray after break-up into the spray cone, the particle size being broadly similar to the ligament diameter. It is a feature of the ligament mode electrostatic spraying herein that a tightly distributed, almost mono-disperse spray is obtained.
- the clean stop performance of the tip valve can be further improved by introducing a pressure relief feature behind the valve. This area will provide a sudden pressure drop when the piston enters this area near completing its forward stroke and enforce immediate and secure closure of the valve with no dripping at the end of the full dose.
- the spray device herein is suitable for spraying into a body cavity, particularly into the nose, mouth or ears of a human.
- the low volume and gentle spray also make it suitable for e.g. ophthalmic spraying.
- the device is a nasal spray device.
- a preferred method of administering a fluid to the nasal cavity from the spray device comprises spraying the fluid into the nasal cavity without substantial penetration of the device into the nostrils.
- without substantial penetration into the nostrils herein is meant that there is no insertion of a nozzle or such-like into the nasal vestibule.
- the nosepiece of the device is preferably placed in contact with the nostril opening to obtain the full benefit of the field intensifying effect described herein in relation to the nosepiece. If pressure is applied by the user, for certainty of contact or to assist in orientation there may be some flaring of the nostril or overlap with the septum cartilage but nevertheless the nosepiece will not be completely surrounded by the nostril.
Landscapes
- Medicinal Preparation (AREA)
- Devices For Dispensing Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Reciprocating Pumps (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
- Loading And Unloading Of Fuel Tanks Or Ships (AREA)
- Sampling And Sample Adjustment (AREA)
- Devices For Use In Laboratory Experiments (AREA)
- Vehicle Body Suspensions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00903272A EP1140368B1 (en) | 1999-01-13 | 2000-01-12 | Dosing and delivering system |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99870004A EP1020233A1 (en) | 1999-01-13 | 1999-01-13 | Dosing and delivering system |
EP99870004 | 1999-01-13 | ||
PCT/US2000/000834 WO2000041816A1 (en) | 1999-01-13 | 2000-01-12 | Dosing and delivering system |
EP00903272A EP1140368B1 (en) | 1999-01-13 | 2000-01-12 | Dosing and delivering system |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1140368A1 true EP1140368A1 (en) | 2001-10-10 |
EP1140368B1 EP1140368B1 (en) | 2003-08-27 |
Family
ID=8243788
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99870004A Withdrawn EP1020233A1 (en) | 1999-01-13 | 1999-01-13 | Dosing and delivering system |
EP00903272A Expired - Lifetime EP1140368B1 (en) | 1999-01-13 | 2000-01-12 | Dosing and delivering system |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99870004A Withdrawn EP1020233A1 (en) | 1999-01-13 | 1999-01-13 | Dosing and delivering system |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP1020233A1 (en) |
JP (1) | JP4295437B2 (en) |
KR (1) | KR20020004944A (en) |
CN (1) | CN1347346A (en) |
AT (1) | ATE248030T1 (en) |
AU (1) | AU748289B2 (en) |
BR (1) | BR0007526A (en) |
CA (1) | CA2360411A1 (en) |
CO (1) | CO5231171A1 (en) |
CZ (1) | CZ20012506A3 (en) |
DE (1) | DE60004780T2 (en) |
EG (1) | EG22672A (en) |
HU (1) | HUP0105057A3 (en) |
IL (1) | IL144092A0 (en) |
MA (1) | MA25341A1 (en) |
NO (1) | NO20013508D0 (en) |
NZ (1) | NZ512600A (en) |
PE (1) | PE20001192A1 (en) |
PL (1) | PL349767A1 (en) |
RU (1) | RU2198740C1 (en) |
SK (1) | SK10062001A3 (en) |
WO (1) | WO2000041816A1 (en) |
ZA (1) | ZA200105289B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
FR2893090A1 (en) * | 2005-11-09 | 2007-05-11 | Claude Jaunay | FLUID PUMPING AND DISPENSING ASSEMBLY |
NL1030992C2 (en) | 2006-01-24 | 2007-07-26 | Airspray Nv | Squeeze foamer. |
GB0602980D0 (en) | 2006-02-14 | 2006-03-29 | Optinose As | Delivery device and method |
CA2740766C (en) * | 2008-10-16 | 2016-02-02 | Automatic Bar Controls, Inc. | Apparatus and method and turntable for on-demand distributing of a food product |
EP2201977A1 (en) | 2008-12-23 | 2010-06-30 | Siegfried Generics International AG | Metering device for creating a gas flow with an active agent |
RU2452585C2 (en) * | 2009-06-03 | 2012-06-10 | Макнейл Аб | Pocket distributor |
WO2011043712A1 (en) * | 2009-10-08 | 2011-04-14 | Shl Group Ab | Metered liquid droplet inhaler |
RU2529397C2 (en) * | 2012-10-04 | 2014-09-27 | Ирина Леонидовна Лисовская | Medicinal electrophoresis device for eye tissues |
GB2507313B (en) * | 2012-10-25 | 2015-09-30 | Tristel Plc | Pump apparatus |
JP5992321B2 (en) * | 2012-12-27 | 2016-09-14 | 株式会社吉野工業所 | Syringe type ejection container |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
DE102013013530A1 (en) * | 2013-08-13 | 2015-03-12 | Dürr Systems GmbH | Application system with cable-guided handling device for moving an application device |
KR101498220B1 (en) * | 2013-08-30 | 2015-03-03 | 삼성중공업 주식회사 | Sealing apparatus for anti-corrosion |
CN108704200A (en) * | 2015-05-16 | 2018-10-26 | 苏州汉方医药有限公司 | The medicine box being made of manual microactuator suspension particle generator and oldenlandia diffusa or oldenlandia diffusa element |
GB2553031B (en) | 2017-06-27 | 2021-12-29 | Kohler Mira Ltd | Additive dispenser |
DE102018121513B4 (en) | 2018-09-04 | 2020-04-02 | Prof. Reymond & Hetzel GbR (vertretungsberechtigter Gesellschafter: Alexander Hetzel, 78667 Villingendorf) | Medical instrument for the directed introduction of a substance into a cavity of a body and tool therefor |
US11666931B2 (en) | 2019-05-14 | 2023-06-06 | Kohler Co. | Inline shower device |
US12031306B2 (en) | 2019-05-14 | 2024-07-09 | Kohler Co. | Inline dispensing device |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR920943A (en) * | 1946-01-30 | 1947-04-22 | ejector for liquids | |
DE3339180C2 (en) * | 1983-10-28 | 1993-10-14 | Pfeiffer Erich Gmbh & Co Kg | Discharge device for media |
US4728006A (en) | 1984-04-27 | 1988-03-01 | The Procter & Gamble Company | Flexible container including self-sealing dispensing valve to provide automatic shut-off and leak resistant inverted storage |
US4991745A (en) | 1989-04-25 | 1991-02-12 | Liquid Molding Systems, Inc. | Dispensing valve with trampoline-like construction |
WO1993002729A1 (en) * | 1990-07-12 | 1993-02-18 | Habley Medical Technology Corporation | Super atomizing nonchlorinated fluorocarbon medication inhaler |
DK302890D0 (en) | 1990-12-21 | 1990-12-21 | Novo Nordisk As | DISPENSER |
EP0597601A1 (en) | 1992-11-13 | 1994-05-18 | National Semiconductor Corporation | Reflexively sizing memory bus interface |
EP0780127A1 (en) | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
WO1997046243A1 (en) | 1996-06-04 | 1997-12-11 | The Procter & Gamble Company | A nasal spray containing an intranasal steroid and an antihistamine |
GB9619445D0 (en) * | 1996-09-18 | 1996-10-30 | Boots Co Plc | Fluid dispenser |
-
1999
- 1999-01-13 EP EP99870004A patent/EP1020233A1/en not_active Withdrawn
-
2000
- 2000-01-12 HU HU0105057A patent/HUP0105057A3/en unknown
- 2000-01-12 KR KR1020017008745A patent/KR20020004944A/en not_active Application Discontinuation
- 2000-01-12 DE DE60004780T patent/DE60004780T2/en not_active Expired - Lifetime
- 2000-01-12 RU RU2001122593/12A patent/RU2198740C1/en not_active IP Right Cessation
- 2000-01-12 IL IL14409200A patent/IL144092A0/en unknown
- 2000-01-12 WO PCT/US2000/000834 patent/WO2000041816A1/en not_active Application Discontinuation
- 2000-01-12 AU AU25046/00A patent/AU748289B2/en not_active Ceased
- 2000-01-12 BR BR0007526-4A patent/BR0007526A/en not_active IP Right Cessation
- 2000-01-12 NZ NZ512600A patent/NZ512600A/en unknown
- 2000-01-12 JP JP2000593418A patent/JP4295437B2/en not_active Expired - Lifetime
- 2000-01-12 PL PL00349767A patent/PL349767A1/en unknown
- 2000-01-12 CO CO00001231A patent/CO5231171A1/en not_active Application Discontinuation
- 2000-01-12 CN CN00802613A patent/CN1347346A/en active Pending
- 2000-01-12 PE PE2000000022A patent/PE20001192A1/en not_active Application Discontinuation
- 2000-01-12 AT AT00903272T patent/ATE248030T1/en not_active IP Right Cessation
- 2000-01-12 CZ CZ20012506A patent/CZ20012506A3/en unknown
- 2000-01-12 EG EG20000030A patent/EG22672A/en active
- 2000-01-12 CA CA002360411A patent/CA2360411A1/en not_active Abandoned
- 2000-01-12 SK SK1006-2001A patent/SK10062001A3/en unknown
- 2000-01-12 EP EP00903272A patent/EP1140368B1/en not_active Expired - Lifetime
-
2001
- 2001-06-27 ZA ZA200105289A patent/ZA200105289B/en unknown
- 2001-07-11 MA MA26264A patent/MA25341A1/en unknown
- 2001-07-13 NO NO20013508A patent/NO20013508D0/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0041816A1 * |
Also Published As
Publication number | Publication date |
---|---|
HUP0105057A3 (en) | 2002-06-28 |
PL349767A1 (en) | 2002-09-09 |
BR0007526A (en) | 2001-11-27 |
EP1140368B1 (en) | 2003-08-27 |
EP1020233A1 (en) | 2000-07-19 |
MA25341A1 (en) | 2001-12-31 |
NO20013508L (en) | 2001-07-13 |
WO2000041816A1 (en) | 2000-07-20 |
NZ512600A (en) | 2002-12-20 |
KR20020004944A (en) | 2002-01-16 |
CZ20012506A3 (en) | 2002-03-13 |
ATE248030T1 (en) | 2003-09-15 |
RU2198740C1 (en) | 2003-02-20 |
AU748289B2 (en) | 2002-05-30 |
SK10062001A3 (en) | 2002-03-05 |
HUP0105057A2 (en) | 2002-04-29 |
JP4295437B2 (en) | 2009-07-15 |
CA2360411A1 (en) | 2000-07-20 |
RU2001122593A (en) | 2004-02-20 |
IL144092A0 (en) | 2002-05-23 |
NO20013508D0 (en) | 2001-07-13 |
DE60004780T2 (en) | 2004-06-17 |
PE20001192A1 (en) | 2000-12-04 |
CO5231171A1 (en) | 2002-12-27 |
EG22672A (en) | 2003-06-30 |
DE60004780D1 (en) | 2003-10-02 |
JP2002534331A (en) | 2002-10-15 |
ZA200105289B (en) | 2002-03-06 |
CN1347346A (en) | 2002-05-01 |
AU2504600A (en) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6471095B1 (en) | Dosing and delivering system | |
EP1140368B1 (en) | Dosing and delivering system | |
AU749158B2 (en) | Nasal spray device with improved spray geometry | |
EP1779933A1 (en) | Dispenser for a liquid | |
AU751624B2 (en) | Nasal spray device with elastomeric valve | |
MXPA01007126A (en) | Dosing and delivering system | |
MXPA00009620A (en) | Nasal spray device with elastomeric valve | |
MXPA00009633A (en) | Nasal spray device with improved spray geometry | |
MX2008005432A (en) | Dispenser for a liquid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010727 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20030827 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030827 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030827 Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030827 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030827 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030827 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030827 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030827 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030827 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60004780 Country of ref document: DE Date of ref document: 20031002 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031127 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031127 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031208 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040112 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040131 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20030827 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20040528 |
|
EN | Fr: translation not filed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20190109 Year of fee payment: 20 Ref country code: DE Payment date: 20190102 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60004780 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20200111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20200111 |